Physician profile
John Jow
NPI 1750364287
$9,637.62
in general payments reported to CMS, 2019-2025
34 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 85% of Prosthodontics providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,077 · 2020: $877 · 2021: $2,243 · 2022: $1,821 · 2023: $968 · 2024: $630 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,149.33 | 2019-2024 | Repatha, Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $878.38 | 2019-2022 | |
| Genentech USA, INC. | $801.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $605.70 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $497.05 | 2020-2025 | Terlivaz |
| Rigel Pharmaceuticals, INC. | $495.66 | 2021-2025 | Rezlidhia, Gavreto, Tavalisse |
| Shire North American Group INC | $485.96 | 2019 | |
| Sanofi-Aventis U.S. LLC | $432.81 | 2019-2023 | |
| Genzyme Corporation | $328.67 | 2021-2024 | |
| Daiichi Sankyo INC. | $296.35 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $269.88 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $259.77 | 2021 | |
| Emd Serono, INC. | $252.81 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $246.27 | 2022-2023 | Opdivo |
| Gilead Sciences, INC. | $237.70 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $228.88 | 2020-2024 | |
| Pfizer INC. | $204.68 | 2019-2025 | |
| Viiv Healthcare Company | $125.00 | 2022 | |
| G1 Therapeutics, INC. | $125.00 | 2022 | |
| Fresenius Kabi USA, LLC | $125.00 | 2023 | Stimufend |
| Grifols USA, LLC | $125.00 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $124.99 | 2019 | |
| Agios Pharmaceuticals, INC. | $124.54 | 2019 | |
| Mirati Therapeutics, INC. | $124.29 | 2023 | Krazati |
| Csl Behring | $124.21 | 2022 | |
| Xeris Pharmaceuticals, INC. | $121.87 | 2020 | |
| Portola Pharmaceuticals, LLC | $119.56 | 2019 | |
| Mylan Specialty L.P. | $116.86 | 2021 | |
| Incyte Corporation | $114.27 | 2019 | |
| Heron Therapeutics, INC. | $113.45 | 2021 | |
| Abbvie INC. | $104.62 | 2023 | |
| Karyopharm Therapeutics INC. | $96.01 | 2022 | |
| Seagen INC. | $93.98 | 2021 | |
| Dynavax Technologies Corporation | $87.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Jow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.